GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Revenue per Share

Sunshine Biopharma (Sunshine Biopharma) Revenue per Share : $1,334.18 (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Revenue per Share?

Sunshine Biopharma's revenue per share for the three months ended in Mar. 2024 was $1,256.83. Sunshine Biopharma's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $1,334.18.

Warning Sign:

Sunshine Biopharma Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue Per Share Growth Rate of Sunshine Biopharma was -45.90% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 140.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Sunshine Biopharma's Revenue per Share or its related term are showing as below:

SBFM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 39.6   Med: 90.2   Max: 140.8
Current: 140.8

During the past 13 years, Sunshine Biopharma's highest 3-Year average Revenue Per Share Growth Rate was 140.80% per year. The lowest was 39.60% per year. And the median was 90.20% per year.

SBFM's 3-Year Revenue Growth Rate is ranked better than
98.16% of 922 companies
in the Drug Manufacturers industry
Industry Median: 6.4 vs SBFM: 140.80

Sunshine Biopharma Revenue per Share Historical Data

The historical data trend for Sunshine Biopharma's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Revenue per Share Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.50 7.10 8.77 28.59 99.15

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,447.00 21.89 23.18 32.27 1,256.83

Competitive Comparison of Sunshine Biopharma's Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's PS Ratio falls into.



Sunshine Biopharma Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Sunshine Biopharma's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=24.093/0.243
=99.15

Sunshine Biopharma's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=7.541/0.006
=1,256.83

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,334.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Biopharma  (NAS:SBFM) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Sunshine Biopharma Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3

Sunshine Biopharma (Sunshine Biopharma) Headlines

From GuruFocus

Sunshine Biopharma Completes Application to Uplist to OTCQB

By ACCESSWIRE ACCESSWIRE 01-27-2021

Sunshine Biopharma: An Opportunity Knocking?

By Ishan Majumdar 05-09-2022